SCHEMBL314496

SCHEMBL314496

CC1CNc2cc(O)ccc2-n2c(-c3ccncc3)nnc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.36
MAPK10 P53779 2/20 0.33
MAPK9 P45984 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
ROCK2 O75116 4/20 0.32
CDK1 P06493 4/20 0.32
PRKACA P17612 4/20 0.32
CDK2 P24941 4/20 0.32
CSNK1D P48730 4/20 0.32
GSK3A P49840 4/20 0.32
CDK5 Q00535 4/20 0.32
PRKCD Q05655 4/20 0.32
ROCK1 Q13464 4/20 0.32
CDC42BPA Q5VT25 4/20 0.32
DYRK3 O43781 3/20 0.32
RPS6KA5 O75582 3/20 0.32
PRKD3 O94806 3/20 0.32
MAP4K4 O95819 3/20 0.32
CLK2 P49760 3/20 0.32
GSK3B P49841 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314883 0.88 ALDH1A1 (0.40) ALDH1A1HPGDHSD17B10
SCHEMBL314881 0.88 ALDH1A1 (0.40) ALDH1A1HPGDHSD17B10
SCHEMBL314882 0.88 ALDH1A1 (0.40) ALDH1A1HPGDHSD17B10
SCHEMBL10098578 0.88 AKT1 (0.42) AKT1SMN1; SMN2
SCHEMBL316012 0.86 TNIK (0.35)
SCHEMBL314273 0.85 TP53 (0.40) BCHEALDH1A1HPGDESR2
SCHEMBL314274 0.85 TP53 (0.40) BCHEALDH1A1HPGDESR2
SCHEMBL314275 0.85 TP53 (0.40) BCHEALDH1A1HPGDESR2
SCHEMBL314780 0.85 ESR2 (0.35) ALDH1A1HPGDESR2HSD17B10LMNA
SCHEMBL315176 0.84 AKT1 (0.37) AKT1ALDH1A1HPGDESR2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US claimed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 CDC7 658/4885MAPK10 1454/4885MAPK9 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.